TUG1 and liver cancer: The down‐regulation of TUG1 in HCC cells can inhibit both PD‐L1 and CD47, which indicates that TUG1 is a potential biomarker and immunotherapeutic target for liver cancer, thereby providing new ideas for enhancing antitumor immunity (Figure 7K).